ACR: Otezla Benefit Durable in PsA

Share this content:
ACR: Otezla Benefit Durable in PsA
ACR: Otezla Benefit Durable in PsA
Among patients receiving 20 mg of apremilast twice daily for 2 years, 20% improvements on the criteria of the American College of Rheumatology (ACR20) were seen in 64.8%, and among those given 30 mg twice daily, 57.3% had ACR20 responses, according to Alvin Wells, MD, PhD, of the Rheumatology and Immunotherapy Center in Franklin, Wisc.
READ FULL ARTICLE From Medical Page Today
Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


is free, fast, and customized just for you!

Already a member?

Sign In Now »